ADMA Biologics Inc
NASDAQ:ADMA

Watchlist Manager
ADMA Biologics Inc Logo
ADMA Biologics Inc
NASDAQ:ADMA
Watchlist
Price: 21.18 USD -0.56% Market Closed
Market Cap: 5B USD
Have any thoughts about
ADMA Biologics Inc?
Write Note

ADMA Biologics Inc
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ADMA Biologics Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
ADMA Biologics Inc
NASDAQ:ADMA
Depreciation & Amortization
-$550.5k
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ADMA Biologics Inc
Glance View

Market Cap
5B USD
Industry
Biotechnology

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 527 full-time employees. The company went IPO on 2013-10-17. The firm is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include ADMA BioManufacturing and Plasma Collection Centers. The Company’s ADMA BioManufacturing segment reflects its immune globulin manufacturing and development operations in Florida. The Plasma Collection Centers segment consists of approximately three plasma collection facilities. Its products include BIVIGAM, ASCENIV and Nabi-HB. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons.

ADMA Intrinsic Value
8.63 USD
Overvaluation 59%
Intrinsic Value
Price

See Also

What is ADMA Biologics Inc's Depreciation & Amortization?
Depreciation & Amortization
-550.5k USD

Based on the financial report for Sep 30, 2024, ADMA Biologics Inc's Depreciation & Amortization amounts to -550.5k USD.

What is ADMA Biologics Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
8%

Over the last year, the Depreciation & Amortization growth was 24%. The average annual Depreciation & Amortization growth rates for ADMA Biologics Inc have been 9% over the past three years , 8% over the past five years .

Back to Top